Hello all, I need help automating the creation of a tree menu. I get a .js file exported from Stellent (I can make this a HTML or text file if need be) and I need to parse out the HTML elements from it to make a tree menu. h1's are chapters, h2's are sections, and h3's are subsections. I also need to parse out he fragment ('#P212_17452') from any h1's and h2's.
Here is the .JS file and below that I will give you what the final treemenu js file. I am not very familiar with parsing out HTMl elements and would like some guidance or a quick example.
.JS file from Stellent
/* Sections.js. */
var pcor_sections = [ 0
/*<html>
<head>
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<title>slicedemo Table of Contents</title>
<meta name="GENERATOR" content="Stellent Content Publisher 7.0">
<meta name="TransitPubID" content="120">
</head>
<body><a name="TopOfPage"> </a>
<!-- TRANSIT - INFOBEFORE -->
<hr size="2" width="80%">
*/ , '<h1><a href="chf%20ES.htm#P0_0" target="_top">Executive Summary </a></h1>' /*
*/ , '<h2><a href="chf%20ES.htm#P6_1060" target="_top">What are the key parameters of the CHF market?</a></h2>' /*
*/ , '<h2><a href="chf%20ES-01.htm#P10_1106" target="_top">What are the factors driving the market for CHF therapies? </a></h2>' /*
*/ , '<h2><a href="chf%20ES-02.htm#P14_2724" target="_top">What factors are constraining the market for CHF therapies? </a></h2>' /*
*/ , '<h2><a href="chf%20ES-03.htm#P17_3692" target="_top">What are the drug development activities of note in CHF? </a></h2>' /*
*/ , '<h2><a href="chf%20ES-04.htm#P21_4848" target="_top">What do the experts say? </a></h2>' /*
*/ , '<h2><a href="chf%20ES-05.htm#P28_6611" target="_top">What key challenges and opportunities remain? </a></h2>' /*
*/ , '<h1><a href="Pharmacor%20Chapter%20Head.htm#P0_0" target="_top">1. Introduction </a></h1>' /*
*/ , '<h1><a href="CHF-EP-cmc.htm#P0_0" target="_top">2. Etiology and Pathophysiology </a></h1>' /*
*/ , '<h2><a href="CHF-EP-cmc.htm#P7_960" target="_top">Etiology and Pathophysiology Overview</a></h2>' /*
*/ , '<h2><a href="CHF-EP-cmc-01.htm#P9_1980" target="_top">Anatomy</a></h2>' /*
*/ , '<h2><a href="CHF-EP-cmc-02.htm#P12_3759" target="_top">Etiology</a></h2>' /*
*/ , '<h3><a href="CHF-EP-cmc-02.htm#P13_3767" target="_top">Causes of Chronic Heart Failure </a></h3>' /*
*/ , '<h3><a href="CHF-EP-cmc-02.htm#P18_5924" target="_top">Clinical Characterization of Chronic Heart Failure </a></h3>' /*
*/ , '<h2><a href="CHF-EP-cmc-03.htm#P21_7226" target="_top">Pathophysiology</a></h2>' /*
*/ , '<h3><a href="CHF-EP-cmc-03.htm#P25_9608" target="_top">Sympathetic Nervous System</a></h3>' /*
*/ , '<h3><a href="CHF-EP-cmc-03.htm#P28_10921" target="_top">Renin-Angiotensin-Aldosterone System</a></h3>' /*
*/ , '<h3><a href="CHF-EP-cmc-03.htm#P34_13615" target="_top">Natriuretic Peptides</a></h3>' /*
*/ , '<h3><a href="CHF-EP-cmc-03.htm#P37_14887" target="_top">Endothelin-1</a></h3>' /*
*/ , '<h3><a href="CHF-EP-cmc-03.htm#P39_15408" target="_top">Immunomodulator Activity in CHF</a></h3>' /*
*/ , '<h1><a href="epi%20mock-up-cmc.htm#P5_0" target="_top">3. Epidemiology</a></h1>' /*
*/ , '<h2><a href="epi%20mock-up-cmc.htm#P38_1150" target="_top">Overview</a></h2>' /*
*/ , '<h2><a href="epi%20mock-up-cmc-01.htm#P41_2865" target="_top">Disease Definition</a></h2>' /*
*/ , '<h2><a href="epi%20mock-up-cmc-02.htm#P44_4463" target="_top">Methodology Overview</a></h2>' /*
*/ , '<h2><a href="epi%20mock-up-cmc-03.htm#P61_16869" target="_top">Major-Market Profiles</a></h2>' /*
*/ , '<h3><a href="epi%20mock-up-cmc-03.htm#P62_16890" target="_top">United States</a></h3>' /*
*/ , '<h3><a href="epi%20mock-up-cmc-03.htm#P65_18532" target="_top">France</a></h3>' /*
*/ , '<h3><a href="epi%20mock-up-cmc-03.htm#P67_19000" target="_top">Germany</a></h3>' /*
*/ , '<h3><a href="epi%20mock-up-cmc-03.htm#P70_20039" target="_top">Italy</a></h3>' /*
*/ , '<h3><a href="epi%20mock-up-cmc-03.htm#P72_21293" target="_top">Spain</a></h3>' /*
*/ , '<h3><a href="epi%20mock-up-cmc-03.htm#P75_23563" target="_top">United Kingdom</a></h3>' /*
*/ , '<h3><a href="epi%20mock-up-cmc-03.htm#P80_26567" target="_top">Japan</a></h3>' /*
*/ , '<h2><a href="epi%20mock-up-cmc-04.htm#P82_27850" target="_top">Subpopulations</a></h2>' /*
*/ , '<h1><a href="CHF-CT-cmc.htm#P5_0" target="_top">4. Current Therapies</a></h1>' /*
*/ , '<h2><a href="CHF-CT-cmc.htm#P12_846" target="_top">Overview of Current Therapies</a></h2>' /*
*/ , '<h2><a href="CHF-CT-cmc-01.htm#P16_3190" target="_top">Angiotensin-Converting Enzyme Inhibitors</a></h2>' /*
*/ , '<h3><a href="CHF-CT-cmc-01.htm#P17_3230" target="_top">Overview</a></h3>' /*
*/ , '<h3><a href="CHF-CT-cmc-01.htm#P23_6331" target="_top">Mechanism of Action</a></h3>' /*
*/ , '<h3><a href="CHF-CT-cmc-01.htm#P27_9912" target="_top">Ramipril</a></h3>' /*
*/ , '<h3><a href="CHF-CT-cmc-01.htm#P31_11868" target="_top">Enalapril</a></h3>' /*
*/ , '<h3><a href="CHF-CT-cmc-01.htm#P36_14438" target="_top">Lisinopril</a></h3>' /*
*/ , '<h2><a href="CHF-CT-cmc-02.htm#P39_15672" target="_top">Angiotensin II Receptor Antagonists </a></h2>' /*
*/ , '<h3><a href="CHF-CT-cmc-02.htm#P40_15708" target="_top">Overview</a></h3>' /*
*/ , '<h3><a href="CHF-CT-cmc-02.htm#P42_16829" target="_top">Mechanism of Action</a></h3>' /*
*/ , '<h3><a href="CHF-CT-cmc-02.htm#P44_17837" target="_top">Valsartan</a></h3>' /*
*/ , '<h3><a href="CHF-CT-cmc-02.htm#P50_22036" target="_top">Candesartan</a></h3>' /*
*/ , '<h2><a href="CHF-CT-cmc-03.htm#P56_26286" target="_top">Diuretics </a></h2>' /*
*/ , '<h3><a href="CHF-CT-cmc-03.htm#P57_26296" target="_top">Overview</a></h3>' /*
*/ , '<h3><a href="CHF-CT-cmc-03.htm#P61_28399" target="_top">Mechanism of Action</a></h3>' /*
*/ , '<h3><a href="CHF-CT-cmc-03.htm#P63_29545" target="_top">Furosemide</a></h3>' /*
*/ , '<h3><a href="CHF-CT-cmc-03.htm#P65_30276" target="_top">Chlorothiazide</a></h3>' /*
*/ , '<h2><a href="CHF-CT-cmc-04.htm#P67_30922" target="_top">Aldosterone Antagonists</a></h2>' /*
*/ , '<h3><a href="CHF-CT-cmc-04.htm#P68_30945" target="_top">Overview</a></h3>' /*
*/ , '<h3><a href="CHF-CT-cmc-04.htm#P70_32123" target="_top">Mechanism of Action</a></h3>' /*
*/ , '<h3><a href="CHF-CT-cmc-04.htm#P73_33147" target="_top">Spironolactone </a></h3>' /*
*/ , '<h3><a href="CHF-CT-cmc-04.htm#P77_35246" target="_top">Eplerenone</a></h3>' /*
*/ , '<h2><a href="CHF-CT-cmc-05.htm#P80_37565" target="_top">Beta Blockers </a></h2>' /*
*/ , '<h3><a href="CHF-CT-cmc-05.htm#P81_37579" target="_top">Overview</a></h3>' /*
*/ , '<h3><a href="CHF-CT-cmc-05.htm#P83_38452" target="_top">Mechanism of Action</a></h3>' /*
*/ , '<h3><a href="CHF-CT-cmc-05.htm#P85_39243" target="_top">Carvedilol</a></h3>' /*
*/ , '<h3><a href="CHF-CT-cmc-05.htm#P89_41813" target="_top">Metoprolol</a></h3>' /*
*/ , '<h3><a href="CHF-CT-cmc-05.htm#P92_43636" target="_top">Bisoprolol</a></h3>' /*
*/ , '<h2><a href="CHF-CT-cmc-06.htm#P95_45111" target="_top">Inotropic Agents</a></h2>' /*
*/ , '<h3><a href="CHF-CT-cmc-06.htm#P96_45127" target="_top">Overview</a></h3>' /*
*/ , '<h3><a href="CHF-CT-cmc-06.htm#P98_45758" target="_top">Mechanism of Action</a></h3>' /*
*/ , '<h3><a href="CHF-CT-cmc-06.htm#P100_46806" target="_top">Digoxin</a></h3>' /*
*/ , '<h2><a href="CHF-CT-cmc-07.htm#P104_48541" target="_top">Nonpharmacological Approaches </a></h2>' /*
*/ , '<h1><a href="chf%20MP-cmc.htm#P0_0" target="_top">5. Medical Practice</a></h1>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P10_746" target="_top">First-Line Therapy</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P11_764" target="_top">Second-Line Therapy</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P12_783" target="_top"><img src="Table%20of%20Contents-1t.gif" border="0" width="9" height="5"></a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P13_783" target="_top">US</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P14_785" target="_top">ACEI + Beta blocker</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P15_804" target="_top">Add Diuretic +/- digoxin</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P16_828" target="_top"><img src="Table%20of%20Contents-2t.gif" border="0" width="8" height="5"></a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P17_828" target="_top">FR</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P18_830" target="_top">Watchful waiting</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P19_846" target="_top">ACEI</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P20_850" target="_top"><img src="Table%20of%20Contents-3t.gif" border="0" width="8" height="5"></a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P21_850" target="_top">GE</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P22_852" target="_top">ACEI</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P23_856" target="_top">Add Diuretic</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P24_868" target="_top"><img src="Table%20of%20Contents-4t.gif" border="0" width="8" height="4"></a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P25_868" target="_top">IT</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P26_870" target="_top">ACEI + Beta blocker</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P27_889" target="_top">Add Diuretic</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P28_901" target="_top"><img src="Table%20of%20Contents-5t.gif" border="0" width="7" height="4"></a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P29_901" target="_top">SP</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P30_903" target="_top">ACEI + Beta blocker</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P31_922" target="_top">Add Diuretic</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P32_934" target="_top"><img src="Table%20of%20Contents-6t.gif" border="0" width="7" height="5"></a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P33_934" target="_top">UK</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P34_936" target="_top">ACEI + Beta blocker</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P35_955" target="_top">Add Diuretic +/- digoxin</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P36_979" target="_top"><img src="Table%20of%20Contents-7t.gif" border="0" width="2" height="2"></a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P37_979" target="_top"><img src="Table%20of%20Contents-8t.gif" border="0" width="6" height="5"></a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P38_979" target="_top">JA</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P39_981" target="_top">ACE</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P40_984" target="_top">Add Diuretic +/- digoxin</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc-01.htm#P42_1008" target="_top">Overview</a></h2>' /*
*/ , '<h3><a href="chf%20MP-cmc-01.htm#P45_2994" target="_top">Disease Prevention and Screening</a></h3>' /*
*/ , '<h3><a href="chf%20MP-cmc-01.htm#P48_5188" target="_top">Diagnosis and Referral </a></h3>' /*
*/ , '<h2><a href="chf%20MP-cmc-02.htm#P76_12051" target="_top">Treatment Guidelines</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc-03.htm#P85_16771" target="_top">Major-Market Profiles </a></h2>' /*
*/ , '<h3><a href="chf%20MP-cmc-03.htm#P86_16793" target="_top">United States </a></h3>' /*
*/ , '<h3><a href="chf%20MP-cmc-03.htm#P92_19859" target="_top">France </a></h3>' /*
*/ , '<h3><a href="chf%20MP-cmc-03.htm#P99_24404" target="_top">Germany </a></h3>' /*
*/ , '<h3><a href="chf%20MP-cmc-03.htm#P105_27369" target="_top">Italy </a></h3>' /*
*/ , '<h3><a href="chf%20MP-cmc-03.htm#P112_31655" target="_top">Spain</a></h3>' /*
*/ , '<h3><a href="chf%20MP-cmc-03.htm#P117_34646" target="_top">United Kingdom</a></h3>' /*
*/ , '<h3><a href="chf%20MP-cmc-03.htm#P126_39532" target="_top">Japan</a></h3>' /*
*/ , '<h1><a href="CHF-UN_cmc.htm#P0_0" target="_top">6. Unmet Needs</a></h1>' /*
*/ , '<h2><a href="CHF-UN_cmc.htm#P7_1160" target="_top">Overview</a></h2>' /*
*/ , '<h3><a href="CHF-UN_cmc.htm#P9_1882" target="_top">More-Efficacious Agents for Classes III and IV Patients </a></h3>' /*
*/ , '<h3><a href="CHF-UN_cmc.htm#P12_2963" target="_top">Increased Use of Existing Drugs in Classes I and II </a></h3>' /*
*/ , '<h3><a href="CHF-UN_cmc.htm#P15_4760" target="_top">Improved Diagnosis </a></h3>' /*
*/ , '<h3><a href="CHF-UN_cmc.htm#P18_6145" target="_top">Improved Compliance </a></h3>' /*
*/ , '<h3><a href="CHF-UN_cmc.htm#P21_7756" target="_top">Improved Surgery </a></h3>' /*
*/ , '<h1><a href="chf%20ET-cmc.htm#P0_0" target="_top">7. Emerging Therapies</a></h1>' /*
*/ , '<h2><a href="chf%20ET-cmc.htm#P6_944" target="_top"><img src="Table%20of%20Contents-9t.gif" border="0" width="96" height="63"></a></h2>' /*
*/ , '<h2><a href="chf%20ET-cmc-01.htm#P8_944" target="_top"><img src="Table%20of%20Contents-10t.gif" border="0" width="96" height="54"></a></h2>' /*
*/ , '<h2><a href="chf%20ET-cmc-02.htm#P9_944" target="_top">Emerging Therapies Overview</a></h2>' /*
*/ , '<h2><a href="chf%20ET-cmc-03.htm#P576_7866" target="_top">Angiotensin II Receptor Antagonists </a></h2>' /*
*/ , '<h3><a href="chf%20ET-cmc-03.htm#P577_7902" target="_top">Overview</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-03.htm#P579_9720" target="_top">Mechanism of Action</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-03.htm#P581_10793" target="_top">Telmisartan</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-03.htm#P584_12451" target="_top">Irbesartan</a></h3>' /*
*/ , '<h2><a href="chf%20ET-cmc-04.htm#P587_13672" target="_top">Vasopeptidase Inhibitors </a></h2>' /*
*/ , '<h3><a href="chf%20ET-cmc-04.htm#P588_13697" target="_top">Overview</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-04.htm#P590_14814" target="_top">Mechanism of Action</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-04.htm#P594_16416" target="_top">Omapatrilat </a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-04.htm#P600_20154" target="_top">Gemopatrilat </a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-04.htm#P602_20615" target="_top">MDL-100240 </a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-04.htm#P604_20947" target="_top">AVE-7688</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-04.htm#P606_21803" target="_top">Sampatrilat</a></h3>' /*
*/ , '<h2><a href="chf%20ET-cmc-05.htm#P608_22274" target="_top">Arginine Vasopressin Receptor Antagonists</a></h2>' /*
*/ , '<h3><a href="chf%20ET-cmc-05.htm#P609_22315" target="_top">Overview</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-05.htm#P612_23143" target="_top">Mechanism of Action</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-05.htm#P615_23933" target="_top">Conivaptan</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-05.htm#P621_26470" target="_top">Tolvaptan </a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-05.htm#P627_29295" target="_top">SR-121463 </a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-05.htm#P629_29941" target="_top">OPC-21268</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-05.htm#P631_30354" target="_top">OPC-31260</a></h3>' /*
*/ , '<h2><a href="chf%20ET-cmc-06.htm#P633_30685" target="_top">Endothelin Receptor Antagonists</a></h2>' /*
*/ , '<h3><a href="chf%20ET-cmc-06.htm#P634_30716" target="_top">Overview</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-06.htm#P636_31127" target="_top">Mechanism of Action </a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-06.htm#P639_31967" target="_top">Bosentan </a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-06.htm#P643_32999" target="_top">J-104132 </a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-06.htm#P645_33587" target="_top">Sitaxsentan </a></h3>' /*
*/ , '<h2><a href="chf%20ET-cmc-07.htm#P649_34532" target="_top">Adenosine A1 Receptor Antagonists </a></h2>' /*
*/ , '<h3><a href="chf%20ET-cmc-07.htm#P650_34566" target="_top">Overview</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-07.htm#P652_35297" target="_top">Mechanism of Action</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-07.htm#P655_35936" target="_top">BG9928 (Adentri)</a></h3>' /*
*/ , '<h2><a href="chf%20ET-cmc-08.htm#P659_36810" target="_top">Anti-TNF-α Agents </a></h2>' /*
*/ , '<h3><a href="chf%20ET-cmc-08.htm#P660_36829" target="_top">Overview </a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-08.htm#P662_37217" target="_top">Mechanism of Action</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-08.htm#P664_37671" target="_top">Etanercept </a></h3>' /*
*/ , '<h2><a href="chf%20ET-cmc-09.htm#P667_39057" target="_top">Nonspecific Auto-Antigen Stimulation</a></h2>' /*
*/ , '<h3><a href="chf%20ET-cmc-09.htm#P668_39093" target="_top">Overview</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-09.htm#P670_39465" target="_top">Mechanism of Action</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-09.htm#P672_40350" target="_top">Celacade</a></h3>' /*
*/ , '<h2><a href="chf%20ET-cmc-10.htm#P675_41499" target="_top">Natriuretic Peptides</a></h2>' /*
*/ , '<h3><a href="chf%20ET-cmc-10.htm#P676_41519" target="_top">Overview</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-10.htm#P678_42403" target="_top">Mechanism of Action</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-10.htm#P680_43279" target="_top">Recombinant BNP (Nesiritide) </a></h3>' /*
*/ , '<h2><a href="chf%20ET-cmc-11.htm#P685_44765" target="_top">Inotropic Agents </a></h2>' /*
*/ , '<h3><a href="chf%20ET-cmc-11.htm#P686_44782" target="_top">Overview</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-11.htm#P689_45781" target="_top">Mechanism of Action</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-11.htm#P693_47202" target="_top">Levosimendan</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-11.htm#P701_53254" target="_top">Enoximone </a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-11.htm#P705_55315" target="_top">Oxypurinol</a></h3>' /*
*/ , '<h2><a href="chf%20ET-cmc-12.htm#P712_57690" target="_top">Dual Neutral Endopeptidase/Endothelin-Converting Enzyme Inhibitors</a></h2>' /*
*/ , '<h3><a href="chf%20ET-cmc-12.htm#P713_57756" target="_top">Overview</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-12.htm#P715_57970" target="_top">Mechanism of Action</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-12.htm#P718_58667" target="_top">SLV-306</a></h3>' /*
*/ , '<h2><a href="chf%20ET-cmc-13.htm#P721_59287" target="_top">Dopamine D2 Receptor Agonists</a></h2>' /*
*/ , '<h3><a href="chf%20ET-cmc-13.htm#P722_59316" target="_top">Overview</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-13.htm#P724_60750" target="_top">Mechanism of Action</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-13.htm#P726_61059" target="_top">Nolomirole</a></h3>' /*
*/ , '<h2><a href="chf%20ET-cmc-14.htm#P728_62218" target="_top">Advanced Glycosylation End-Point Breakers</a></h2>' /*
*/ , '<h3><a href="chf%20ET-cmc-14.htm#P729_62259" target="_top">Overview</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-14.htm#P731_62805" target="_top">Mechanism of Action</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-14.htm#P733_63041" target="_top">ALT-711</a></h3>' /*
*/ , '<h1><a href="CHF-MKTcmc.htm#P5_0" target="_top">8. Market Outlook</a></h1>' /*
*/ , '<h2><a href="CHF-MKTcmc.htm#P12_1200" target="_top">Overview</a></h2>' /*
*/ , '<h2><a href="CHF-MKTcmc-01.htm#P27_5555" target="_top">Drug-Class-Specific Trends</a></h2>' /*
*/ , '<h3><a href="CHF-MKTcmc-01.htm#P28_5581" target="_top">Angiotensin-Converting Enzyme Inhibitors</a></h3>' /*
*/ , '<h3><a href="CHF-MKTcmc-01.htm#P32_7215" target="_top">Angiotensin II Receptor Antagonists</a></h3>' /*
*/ , '<h3><a href="CHF-MKTcmc-01.htm#P37_9005" target="_top">Beta Blockers</a></h3>' /*
*/ , '<h3><a href="CHF-MKTcmc-01.htm#P40_10052" target="_top">Diuretics</a></h3>' /*
*/ , '<h3><a href="CHF-MKTcmc-01.htm#P44_10660" target="_top">Aldosterone Antagonists </a></h3>' /*
*/ , '<h3><a href="CHF-MKTcmc-01.htm#P47_11662" target="_top">Inotropic Agents</a></h3>' /*
*/ , '<h3><a href="CHF-MKTcmc-01.htm#P50_12388" target="_top">Vasopeptidase Inhibitors</a></h3>' /*
*/ , '<h3><a href="CHF-MKTcmc-01.htm#P52_12897" target="_top">Arginine Vasopressin Antagonists</a></h3>' /*
*/ , '<h3><a href="CHF-MKTcmc-01.htm#P55_13356" target="_top">Natriuretic Peptides</a></h3>' /*
*/ , '<h2><a href="CHF-MKTcmc-02.htm#P57_13644" target="_top">Region-Specific Trends </a></h2>' /*
*/ , '<h1><a href="Bibiography.htm#P0_0" target="_top">Appendix A. Bibliography—Chronic Heart Failure</a></h1>' /*
*/ , '<h1><a href="Experts%20Interviewed.htm#P0_0" target="_top">Appendix C. Experts Interviewed—Chronic Heart Failure</a></h1>' /*
*/ , '<h1><a href="Market%20Forecast%20Methodology.htm#P0_0" target="_top">Appendix B. Market Forecast Methodology</a></h1>' /*
*/ , '<h2><a href="Market%20Forecast%20Methodology.htm#P1_39" target="_top">General Statement About Patient Population</a></h2>' /*
*/ , '<h2><a href="Market%20Forecast%20Methodology-01.htm#P3_469" target="_top">General Sources of Data </a></h2>' /*
*/ , '<h2><a href="Market%20Forecast%20Methodology-02.htm#P5_1007" target="_top">Definitions of Agents Included in Class Categories </a></h2>' /*
*/ , '<h2><a href="Market%20Forecast%20Methodology-03.htm#P8_1260" target="_top">General Statements About Pricing</a></h2>' /*
*/ , '<h2><a href="Market%20Forecast%20Methodology-04.htm#P31_3491" target="_top">Pricing Assumptions </a></h2>' /*
*/ , '<h3><a href="Market%20Forecast%20Methodology-04.htm#P36_4308" target="_top">Days of Therapy and Compliance</a></h3>' /*
*/ , '<h3><a href="Market%20Forecast%20Methodology-04.htm#P39_5234" target="_top">Emerging Therapy Prices</a></h3>' /*
*/ , '<h2><a href="Market%20Forecast%20Methodology-05.htm#P42_5870" target="_top">Significant Events Impacting the Disease Marketplace</a></h2>' /*
*/ , '<h3><a href="Market%20Forecast%20Methodology-05.htm#P43_5922" target="_top">Percentage Diagnosed</a></h3>' /*
*/ , '<h3><a href="Market%20Forecast%20Methodology-05.htm#P45_6470" target="_top">Percentage Drug-Treated</a></h3>' /*
*/ , '<h3><a href="Market%20Forecast%20Methodology-05.htm#P47_6882" target="_top">Patient Share</a></h3>' /*<!-- TRANSIT - INFOAFTER -->
</body>
</html> */
The tree_nodes.js (final).
var TREE_NODES = [
f(["Executive Summary", "chf-ES.htm", null,
f(["Key Findings", "chf-ES.htm", null]),
f(["What are the key parameters of the CHF market?", "chf-ES-cmc-00.htm", null]),
f(["What are the factors driving the market for CHF therapies?", "chf-ES-01.htm", null]),
f(["What factors are constraining the market for CHF therapies?", "chf-ES-02.htm", null]),
f(["What are the drug development activities of note in CHF?", "chf-ES-03.htm", null]),
f(["What do the experts say?", "chf-ES-04.htm", null]),
f(["What key challenges and opportunities remain?", "chf-ES-05.htm", null])
]),
f(["Introduction", "Pharmacor-Chapter-Head.htm", null,{format:{isFolder:true}}]),
f(["Etiology & Pathophysiology", "CHF-EP-cmc.htm", null,
f(["Key Findings", "CHF-EP-cmc.htm", null]),
f(["Overview", "CHF-EP-cmc-00.htm", null]),
f(["Anatomy", "chf-EP-cmc-01.htm", null]),
f(["Etiology", "CHF-EP-cmc-02.htm", null,
f(["Causes of Chronic Heart Failure", "CHF-EP-cmc-02.htm#P13_3767", null]),
f(["Clinical Characterization of Chronic Heart Failure", "CHF-EP-cmc-02.htm#P18_5924", null])
]),
f(["Pathophysiology", "CHF-EP-cmc-03.htm", null,
f(["Sympathetic Nervous System", "CHF-EP-cmc-03.htm#P25_9608", null]),
f(["Renin-Angiotensin-Aldosterone System", "CHF-EP-cmc-03.htm#P28_10921", null]),
f(["Natriuretic Peptides", "CHF-EP-cmc-03.htm#P34_13615", null]),
f(["Endothelin-1", "CHF-EP-cmc-03.htm#P37_14887", null]),
f([{id:1234}, "Immunomodulator Activity in CHF", "CHF-EP-cmc-03.htm#P39_15408", null])
]) ]),
f(["Epidemiology", "epi-mock-up-cmc.htm", null,
f(["Key Findings", "epi-mock-up-cmc.htm", null]),
f(["Overview", "epi-mock-up-cmc-00.htm", null]),
f(["Disease Definition", "epi-mock-up-cmc-01.htm", null]),
f(["Methodology Overview", "epi-mock-up-cmc-02.htm", null]),
f(["Major-Market Profiles", "epi-mock-up-cmc-03.htm", null,
f(["United States", "epi-mock-up-cmc-03.htm#P62_16890", null]),
f(["France", "epi-mock-up-cmc-03.htm#P65_18532", null]),
f(["Germany", "epi-mock-up-cmc-03.htm#P67_19000", null]),
f(["Italy", "epi-mock-up-cmc-03.htm#P70_20039", null]),
f(["Spain", "epi-mock-up-cmc-03.htm#P72_21293", null]),
f(["United Kingdom", "epi-mock-up-cmc-03.htm#P75_23563", null]),
f(["Japan", "epi-mock-up-cmc-03.htm#P80_26567", null])
]),
f(["Subpopulations","epi-mock-up-cmc-04.htm", null])
]),
f(["Current Therapies", "CHF-CT-cmc.htm", null,
f(["Key Findings", "CHF-CT-cmc.htm", null]),
f(["Overview", "CHF-CT-cmc-00.htm", null]),
f(["Angiotensin-Converting Enzyme Inhibitors", "CHF-CT-cmc-01.htm", null,
f(["Overview", "CHF-CT-cmc-01.htm#P17_3230", null]),
f(["Mechanism of Action", "CHF-CT-cmc-01.htm#P23_6331", null]),
f(["Ramipril", "CHF-CT-cmc-01.htm#P27_9912", null]),
f(["Enalapril", "CHF-CT-cmc-01.htm#P31_11868", null]),
f(["Lisinopril", "CHF-CT-cmc-01.htm#P36_14438", null])
]),
f(["Angiotensin II Receptor Antagonists","CHF-CT-cmc-02.htm", null,
f(["Overview", "CHF-CT-cmc-02.htm#P40_15708", null]),
f(["Mechanism of Action", "CHF-CT-cmc-02.htm#P42_16829", null]),
f(["Valsartan", "CHF-CT-cmc-02.htm#P44_17837", null]),
f(["Candesartan", "CHF-CT-cmc-02.htm#P50_22036", null])
]),
f(["Diuretics","CHF-CT-cmc-03.htm", null,
f(["Overview", "CHF-CT-cmc-03.htm#P57_26296", null]),
f(["Mechanism of Action", "CHF-CT-cmc-03.htm#P61_28399", null]),
f(["Furosemide", "CHF-CT-cmc-03.htm#P63_29545", null]),
f(["Chlorothiazide", "CHF-CT-cmc-03.htm#P65_30276", null])
]),
f(["Aldosterone Antagonists","CHF-CT-cmc-04.htm", null,
f(["Overview", "CHF-CT-cmc-04.htm#P68_30945", null]),
f(["Mechanism of Action", "CHF-CT-cmc-03.htm#P61_28399", null]),
f(["Spironolactone", "CHF-CT-cmc-04.htm#P73_33147", null]),
f(["Eplerenone", "CHF-CT-cmc-04.htm#P77_35246", null])
]),
f(["Beta Blockers ","CHF-CT-cmc-05.htm", null,
f(["Overview", "CHF-CT-cmc-03.htm#P57_26296", null]),
f(["Mechanism of Action", "CHF-CT-cmc-05.htm#P83_38452", null]),
f(["Carvedilol", "CHF-CT-cmc-05.htm#P85_39243", null]),
f(["Metoprolol", "CHF-CT-cmc-05.htm#P89_41813", null]),
f(["Bisoprolol", "CHF-CT-cmc-05.htm#P92_43636", null])
]),
f(["Inotropic Agents","CHF-CT-cmc-06.htm", null,
f(["Overview", "CHF-CT-cmc-06.htm#P96_45127", null]),
f(["Mechanism of Action", "CHF-CT-cmc-06.htm#P98_45758", null]),
f(["Digoxin", "CHF-CT-cmc-06.htm#P100_46806", null])
]),
f(["Nonpharmacological Approaches ","CHF-CT-cmc-07.htm", null])
]),
f(["Medical Practice", "chf-MP-cmc.htm", null,
f(["Key Findings", "chf-MP-cmc.htm", null]),
f(["Overview", "chf-MP-cmc-01.htm", null,
f(["Disease Prevention and Screening", "chf-MP-cmc-01.htm#P45_2994", null]),
f(["Diagnosis and Referral", "chf-MP-cmc-01.htm#P48_5188", null])
]),
f(["Treatment Guidelines","chf-MP-cmc-02.htm", null]),
f(["Major-Market Profiles","chf-MP-cmc-03.htm", null,
f(["United States", "chf-MP-cmc-03.htm#P86_16793", null]),
f(["France", "chf-MP-cmc-03.htm#P92_19859", null]),
f(["Germany", "chf-MP-cmc-03.htm#P99_24404", null]),
f(["Italy", "chf-MP-cmc-03.htm#P105_27369", null]),
f(["Spain", "chf-MP-cmc-03.htm#P112_31655", null]),
f(["United Kingdom", "chf-MP-cmc-03.htm#P117_34646", null]),
f(["Japan", "chf-MP-cmc-03.htm#P126_39532", null])
]) ]),
f(["Unmet Needs", "CHF-UN_cmc.htm", null,
f(["Key Findings", "CHF-UN_cmc.htm", null]),
f(["Overview", "CHF-UN_cmc-00.htm", null,
f(["More-Efficacious Agents for Classes III and IV Patients", "CHF-UN_cmc-00.htm#P9_1882", null]),
f(["Increased Use of Existing Drugs in Classes I and II", "CHF-UN_cmc-00.htm#P12_2963", null]),
f(["Improved Diagnosis", "CHF-UN_cmc-00.htm#P15_4760", null]),
f(["Improved Compliance", "CHF-UN_cmc-00.htm#P18_6145", null]),
f(["Improved Surgery", "CHF-UN_cmc-00.htm#P21_7756", null])
]) ]),
f(["Emerging Therapies", "chf-ET-cmc.htm", null,
f(["Key Findings", "chf-ET-cmc.htm", null]),
f(["Emerging Therapies Overview", "chf-ET-cmc-02.htm", null]),
f(["Angiotensin II Receptor Antagonists", "chf-ET-cmc-03.htm", null,
f(["Overview", "chf-ET-cmc-03.htm#P577_7902", null]),
f(["Mechanism of Action", "chf-ET-cmc-03.htm#P579_9720", null]),
f(["Telmisartan", "chf-ET-cmc-03.htm#P581_10793", null]),
f(["Irbesartan", "chf-ET-cmc-03.htm#P584_12451", null])
]),
f(["Vasopeptidase Inhibitors", "chf-ET-cmc-04.htm", null,
f(["Overview", "chf-ET-cmc-04.htm#P588_13697", null]),
f(["Mechanism of Action", "chf-ET-cmc-04.htm#P590_14814", null]),
f(["Omapatrilat", "chf-ET-cmc-04.htm#P594_16416", null]),
f(["Gemopatrilat", "chf-ET-cmc-04.htm#P600_20154", null]),
f(["MDL-100240", "chf-ET-cmc-04.htm#P602_20615", null]),
f(["AVE-7688", "chf-ET-cmc-04.htm#P604_20947", null]),
f(["Sampatrilat", "chf-ET-cmc-04.htm#P606_21803", null])
]),
f(["Arginine Vasopressin Receptor Antagonists", "chf-ET-cmc-05.htm", null,
f(["Overview", "chf-ET-cmc-05.htm#P609_22315", null]),
f(["Mechanism of Action", "chf-ET-cmc-05.htm#P612_23143", null]),
f(["Conivaptan", "chf-ET-cmc-05.htm#P615_23933", null]),
f(["Tolvaptan", "chf-ET-cmc-05.htm#P621_26470", null]),
f(["SR-121463", "chf-ET-cmc-05.htm#P627_29295", null]),
f(["OPC-21268", "chf-ET-cmc-05.htm#P629_29941", null]),
f(["OPC-31260", "chf-ET-cmc-05.htm#P631_30354", null])
]),
f(["Endothelin Receptor Antagonists", "chf-ET-cmc-06.htm", null,
f(["Overview", "chf-ET-cmc-06.htm#P634_30716", null]),
f(["Mechanism of Action", "chf-ET-cmc-06.htm#P636_31127", null]),
f(["Bosentan", "chf-ET-cmc-06.htm#P639_31967", null]),
f(["J-104132", "chf-ET-cmc-06.htm#P643_32999", null]),
f(["Sitaxsentan", "chf-ET-cmc-06.htm#P645_33587", null])
]),
f(["Adenosine A1 Receptor Antagonists", "chf-ET-cmc-07.htm", null,
f(["Overview", "chf-ET-cmc-07.htm#P650_34566", null]),
f(["Mechanism of Action", "chf-ET-cmc-07.htm#P652_35297", null]),
f(["BG9928 (Adentri)", "chf-ET-cmc-07.htm#P655_35936", null])
]),
f(["Anti-TNF-\u03b1 Agents", "chf-ET-cmc-08.htm", null,
f(["Overview", "chf-ET-cmc-08.htm#P660_36829", null]),
f(["Mechanism of Action", "chf-ET-cmc-08.htm#P662_37217", null]),
f(["Etanercept", "chf-ET-cmc-08.htm#P664_37671", null])
]),
f(["Nonspecific Auto-Antigen Stimulation", "chf-ET-cmc-09.htm", null,
f(["Overview", "chf-ET-cmc-09.htm#P668_39093", null]),
f(["Mechanism of Action", "chf-ET-cmc-09.htm#P670_39465", null]),
f(["Celacade", "chf-ET-cmc-09.htm#P672_40350", null])
]),
f(["Natriuretic Peptides", "chf-ET-cmc-10.htm", null,
f(["Overview", "chf-ET-cmc-10.htm#P676_41519", null]),
f(["Mechanism of Action", "chf-ET-cmc-10.htm#P678_42403", null]),
f(["Recombinant BNP (Nesiritide)", "chf-ET-cmc-10.htm#P680_43279", null])
]),
f(["Inotropic Agents", "chf-ET-cmc-11.htm", null,
f(["Overview", "chf-ET-cmc-11.htm#P686_44782", null]),
f(["Mechanism of Action", "chf-ET-cmc-11.htm#P689_45781", null]),
f(["Levosimendan", "chf-ET-cmc-11.htm#P693_47202", null]),
f(["Enoximone", "chf-ET-cmc-11.htm#P701_53254", null]),
f(["Oxypurinol", "chf-ET-cmc-11.htm#P705_55315", null])
]),
f(["Dual Neutral Endopeptidase/Endothelin-Converting Enzyme Inhibitors", "chf-ET-cmc-12.htm", null,
f(["Overview", "chf-ET-cmc-12.htm#P713_57756", null]),
f(["Mechanism of Action", "chf-ET-cmc-12.htm#P715_57970", null]),
f(["SLV-306", "chf-ET-cmc-12.htm#P718_58667", null])
]),
f(["Dopamine D2 Receptor Agonists", "chf-ET-cmc-13.htm", null,
f(["Overview", "chf-ET-cmc-13.htm#P722_59316", null]),
f(["Mechanism of Action", "chf-ET-cmc-13.htm#P724_60750", null]),
f(["Nolomirole", "chf-ET-cmc-13.htm#P726_61059", null])
]),
f(["Advanced Glycosylation End-Point Breakers", "chf-ET-cmc-14.htm", null,
f(["Overview", "chf-ET-cmc-14.htm#P729_62259", null]),
f(["Mechanism of Action", "chf-ET-cmc-14.htm#P731_62805", null]),
f(["ALT-711", "chf-ET-cmc-14.htm#P733_63041", null])
]) ]),
f(["Market Outlook", "CHF-MKTcmc.htm", null,
f(["Key Findings", "CHF-MKTcmc.htm", null]),
f(["Overview", "CHF-MKTcmc-00.htm", null]),
f(["Drug-Class-Specific Trends", "CHF-MKTcmc-01.htm", null,
f(["Angiotensin-Converting Enzyme Inhibitors", "CHF-MKTcmc-01.htm#P28_5581", null]),
f(["Angiotensin II Receptor Antagonists", "CHF-MKTcmc-01.htm#P32_7215", null]),
f(["Beta Blockers", "CHF-MKTcmc-01.htm#P37_9005", null]),
f(["Diuretics", "CHF-MKTcmc-01.htm#P40_10052", null]),
f(["Aldosterone Antagonists", "CHF-MKTcmc-01.htm#P44_10660", null]),
f(["Inotropic Agents", "CHF-MKTcmc-01.htm#P47_11662", null]),
f(["Vasopeptidase Inhibitors", "CHF-MKTcmc-01.htm#P50_12388", null]),
f(["Arginine Vasopressin Antagonists", "CHF-MKTcmc-01.htm#P52_12897", null]),
f(["Natriuretic Peptides", "CHF-MKTcmc-01.htm#P55_13356", null])
]),
f(["Region-Specific Trends", "CHF-MKTcmc-02.htm", null])
]),
f(["Bibliography", "Bibiography.htm", null,{format:{isFolder:true}}]),
f(["Experts Interviewed", "Experts%20Interviewed.htm", null,{format:{isFolder:true}}]),
f(["Market Forecast Methodology", "Market-Forecast-Methodology.htm", null,
f(["General Statement About Patient Population", "Market-Forecast-Methodology.htm", null]),
f(["General Sources of Data", "Market-Forecast-Methodology-01.htm", null]),
f(["Definitions of Agents Included in Class Categories", "Market-Forecast-Methodology-02.htm", null]),
f(["General Statements About Pricing", "Market-Forecast-Methodology-03.htm", null]),
f(["Pricing Assumptions", "Market-Forecast-Methodology-04.htm", null,
f(["Days of Therapy and Compliance", "Market-Forecast-Methodology-04.htm#P36_4308", null]),
f(["Emerging Therapy Prices", "Market-Forecast-Methodology-04.htm#P39_5234", null]) ]),
f(["Significant Events Impacting the Disease Marketplace", "Market-Forecast-Methodology-05.htm", null,
f(["Percentage Diagnosed", "Market-Forecast-Methodology-05.htm#P43_5922", null]),
f(["Percentage Drug-Treated", "Market-Forecast-Methodology-05.htm#P45_6470", null]),
f(["Patient Share", "Market-Forecast-Methodology-05.htm#P47_6882", null])
]),
f(["Market Assumptions","Market%20Assumptions.htm",null])
])
];
Thanks
Here is the .JS file and below that I will give you what the final treemenu js file. I am not very familiar with parsing out HTMl elements and would like some guidance or a quick example.
.JS file from Stellent
/* Sections.js. */
var pcor_sections = [ 0
/*<html>
<head>
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<title>slicedemo Table of Contents</title>
<meta name="GENERATOR" content="Stellent Content Publisher 7.0">
<meta name="TransitPubID" content="120">
</head>
<body><a name="TopOfPage"> </a>
<!-- TRANSIT - INFOBEFORE -->
<hr size="2" width="80%">
*/ , '<h1><a href="chf%20ES.htm#P0_0" target="_top">Executive Summary </a></h1>' /*
*/ , '<h2><a href="chf%20ES.htm#P6_1060" target="_top">What are the key parameters of the CHF market?</a></h2>' /*
*/ , '<h2><a href="chf%20ES-01.htm#P10_1106" target="_top">What are the factors driving the market for CHF therapies? </a></h2>' /*
*/ , '<h2><a href="chf%20ES-02.htm#P14_2724" target="_top">What factors are constraining the market for CHF therapies? </a></h2>' /*
*/ , '<h2><a href="chf%20ES-03.htm#P17_3692" target="_top">What are the drug development activities of note in CHF? </a></h2>' /*
*/ , '<h2><a href="chf%20ES-04.htm#P21_4848" target="_top">What do the experts say? </a></h2>' /*
*/ , '<h2><a href="chf%20ES-05.htm#P28_6611" target="_top">What key challenges and opportunities remain? </a></h2>' /*
*/ , '<h1><a href="Pharmacor%20Chapter%20Head.htm#P0_0" target="_top">1. Introduction </a></h1>' /*
*/ , '<h1><a href="CHF-EP-cmc.htm#P0_0" target="_top">2. Etiology and Pathophysiology </a></h1>' /*
*/ , '<h2><a href="CHF-EP-cmc.htm#P7_960" target="_top">Etiology and Pathophysiology Overview</a></h2>' /*
*/ , '<h2><a href="CHF-EP-cmc-01.htm#P9_1980" target="_top">Anatomy</a></h2>' /*
*/ , '<h2><a href="CHF-EP-cmc-02.htm#P12_3759" target="_top">Etiology</a></h2>' /*
*/ , '<h3><a href="CHF-EP-cmc-02.htm#P13_3767" target="_top">Causes of Chronic Heart Failure </a></h3>' /*
*/ , '<h3><a href="CHF-EP-cmc-02.htm#P18_5924" target="_top">Clinical Characterization of Chronic Heart Failure </a></h3>' /*
*/ , '<h2><a href="CHF-EP-cmc-03.htm#P21_7226" target="_top">Pathophysiology</a></h2>' /*
*/ , '<h3><a href="CHF-EP-cmc-03.htm#P25_9608" target="_top">Sympathetic Nervous System</a></h3>' /*
*/ , '<h3><a href="CHF-EP-cmc-03.htm#P28_10921" target="_top">Renin-Angiotensin-Aldosterone System</a></h3>' /*
*/ , '<h3><a href="CHF-EP-cmc-03.htm#P34_13615" target="_top">Natriuretic Peptides</a></h3>' /*
*/ , '<h3><a href="CHF-EP-cmc-03.htm#P37_14887" target="_top">Endothelin-1</a></h3>' /*
*/ , '<h3><a href="CHF-EP-cmc-03.htm#P39_15408" target="_top">Immunomodulator Activity in CHF</a></h3>' /*
*/ , '<h1><a href="epi%20mock-up-cmc.htm#P5_0" target="_top">3. Epidemiology</a></h1>' /*
*/ , '<h2><a href="epi%20mock-up-cmc.htm#P38_1150" target="_top">Overview</a></h2>' /*
*/ , '<h2><a href="epi%20mock-up-cmc-01.htm#P41_2865" target="_top">Disease Definition</a></h2>' /*
*/ , '<h2><a href="epi%20mock-up-cmc-02.htm#P44_4463" target="_top">Methodology Overview</a></h2>' /*
*/ , '<h2><a href="epi%20mock-up-cmc-03.htm#P61_16869" target="_top">Major-Market Profiles</a></h2>' /*
*/ , '<h3><a href="epi%20mock-up-cmc-03.htm#P62_16890" target="_top">United States</a></h3>' /*
*/ , '<h3><a href="epi%20mock-up-cmc-03.htm#P65_18532" target="_top">France</a></h3>' /*
*/ , '<h3><a href="epi%20mock-up-cmc-03.htm#P67_19000" target="_top">Germany</a></h3>' /*
*/ , '<h3><a href="epi%20mock-up-cmc-03.htm#P70_20039" target="_top">Italy</a></h3>' /*
*/ , '<h3><a href="epi%20mock-up-cmc-03.htm#P72_21293" target="_top">Spain</a></h3>' /*
*/ , '<h3><a href="epi%20mock-up-cmc-03.htm#P75_23563" target="_top">United Kingdom</a></h3>' /*
*/ , '<h3><a href="epi%20mock-up-cmc-03.htm#P80_26567" target="_top">Japan</a></h3>' /*
*/ , '<h2><a href="epi%20mock-up-cmc-04.htm#P82_27850" target="_top">Subpopulations</a></h2>' /*
*/ , '<h1><a href="CHF-CT-cmc.htm#P5_0" target="_top">4. Current Therapies</a></h1>' /*
*/ , '<h2><a href="CHF-CT-cmc.htm#P12_846" target="_top">Overview of Current Therapies</a></h2>' /*
*/ , '<h2><a href="CHF-CT-cmc-01.htm#P16_3190" target="_top">Angiotensin-Converting Enzyme Inhibitors</a></h2>' /*
*/ , '<h3><a href="CHF-CT-cmc-01.htm#P17_3230" target="_top">Overview</a></h3>' /*
*/ , '<h3><a href="CHF-CT-cmc-01.htm#P23_6331" target="_top">Mechanism of Action</a></h3>' /*
*/ , '<h3><a href="CHF-CT-cmc-01.htm#P27_9912" target="_top">Ramipril</a></h3>' /*
*/ , '<h3><a href="CHF-CT-cmc-01.htm#P31_11868" target="_top">Enalapril</a></h3>' /*
*/ , '<h3><a href="CHF-CT-cmc-01.htm#P36_14438" target="_top">Lisinopril</a></h3>' /*
*/ , '<h2><a href="CHF-CT-cmc-02.htm#P39_15672" target="_top">Angiotensin II Receptor Antagonists </a></h2>' /*
*/ , '<h3><a href="CHF-CT-cmc-02.htm#P40_15708" target="_top">Overview</a></h3>' /*
*/ , '<h3><a href="CHF-CT-cmc-02.htm#P42_16829" target="_top">Mechanism of Action</a></h3>' /*
*/ , '<h3><a href="CHF-CT-cmc-02.htm#P44_17837" target="_top">Valsartan</a></h3>' /*
*/ , '<h3><a href="CHF-CT-cmc-02.htm#P50_22036" target="_top">Candesartan</a></h3>' /*
*/ , '<h2><a href="CHF-CT-cmc-03.htm#P56_26286" target="_top">Diuretics </a></h2>' /*
*/ , '<h3><a href="CHF-CT-cmc-03.htm#P57_26296" target="_top">Overview</a></h3>' /*
*/ , '<h3><a href="CHF-CT-cmc-03.htm#P61_28399" target="_top">Mechanism of Action</a></h3>' /*
*/ , '<h3><a href="CHF-CT-cmc-03.htm#P63_29545" target="_top">Furosemide</a></h3>' /*
*/ , '<h3><a href="CHF-CT-cmc-03.htm#P65_30276" target="_top">Chlorothiazide</a></h3>' /*
*/ , '<h2><a href="CHF-CT-cmc-04.htm#P67_30922" target="_top">Aldosterone Antagonists</a></h2>' /*
*/ , '<h3><a href="CHF-CT-cmc-04.htm#P68_30945" target="_top">Overview</a></h3>' /*
*/ , '<h3><a href="CHF-CT-cmc-04.htm#P70_32123" target="_top">Mechanism of Action</a></h3>' /*
*/ , '<h3><a href="CHF-CT-cmc-04.htm#P73_33147" target="_top">Spironolactone </a></h3>' /*
*/ , '<h3><a href="CHF-CT-cmc-04.htm#P77_35246" target="_top">Eplerenone</a></h3>' /*
*/ , '<h2><a href="CHF-CT-cmc-05.htm#P80_37565" target="_top">Beta Blockers </a></h2>' /*
*/ , '<h3><a href="CHF-CT-cmc-05.htm#P81_37579" target="_top">Overview</a></h3>' /*
*/ , '<h3><a href="CHF-CT-cmc-05.htm#P83_38452" target="_top">Mechanism of Action</a></h3>' /*
*/ , '<h3><a href="CHF-CT-cmc-05.htm#P85_39243" target="_top">Carvedilol</a></h3>' /*
*/ , '<h3><a href="CHF-CT-cmc-05.htm#P89_41813" target="_top">Metoprolol</a></h3>' /*
*/ , '<h3><a href="CHF-CT-cmc-05.htm#P92_43636" target="_top">Bisoprolol</a></h3>' /*
*/ , '<h2><a href="CHF-CT-cmc-06.htm#P95_45111" target="_top">Inotropic Agents</a></h2>' /*
*/ , '<h3><a href="CHF-CT-cmc-06.htm#P96_45127" target="_top">Overview</a></h3>' /*
*/ , '<h3><a href="CHF-CT-cmc-06.htm#P98_45758" target="_top">Mechanism of Action</a></h3>' /*
*/ , '<h3><a href="CHF-CT-cmc-06.htm#P100_46806" target="_top">Digoxin</a></h3>' /*
*/ , '<h2><a href="CHF-CT-cmc-07.htm#P104_48541" target="_top">Nonpharmacological Approaches </a></h2>' /*
*/ , '<h1><a href="chf%20MP-cmc.htm#P0_0" target="_top">5. Medical Practice</a></h1>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P10_746" target="_top">First-Line Therapy</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P11_764" target="_top">Second-Line Therapy</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P12_783" target="_top"><img src="Table%20of%20Contents-1t.gif" border="0" width="9" height="5"></a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P13_783" target="_top">US</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P14_785" target="_top">ACEI + Beta blocker</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P15_804" target="_top">Add Diuretic +/- digoxin</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P16_828" target="_top"><img src="Table%20of%20Contents-2t.gif" border="0" width="8" height="5"></a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P17_828" target="_top">FR</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P18_830" target="_top">Watchful waiting</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P19_846" target="_top">ACEI</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P20_850" target="_top"><img src="Table%20of%20Contents-3t.gif" border="0" width="8" height="5"></a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P21_850" target="_top">GE</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P22_852" target="_top">ACEI</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P23_856" target="_top">Add Diuretic</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P24_868" target="_top"><img src="Table%20of%20Contents-4t.gif" border="0" width="8" height="4"></a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P25_868" target="_top">IT</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P26_870" target="_top">ACEI + Beta blocker</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P27_889" target="_top">Add Diuretic</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P28_901" target="_top"><img src="Table%20of%20Contents-5t.gif" border="0" width="7" height="4"></a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P29_901" target="_top">SP</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P30_903" target="_top">ACEI + Beta blocker</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P31_922" target="_top">Add Diuretic</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P32_934" target="_top"><img src="Table%20of%20Contents-6t.gif" border="0" width="7" height="5"></a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P33_934" target="_top">UK</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P34_936" target="_top">ACEI + Beta blocker</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P35_955" target="_top">Add Diuretic +/- digoxin</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P36_979" target="_top"><img src="Table%20of%20Contents-7t.gif" border="0" width="2" height="2"></a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P37_979" target="_top"><img src="Table%20of%20Contents-8t.gif" border="0" width="6" height="5"></a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P38_979" target="_top">JA</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P39_981" target="_top">ACE</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc.htm#P40_984" target="_top">Add Diuretic +/- digoxin</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc-01.htm#P42_1008" target="_top">Overview</a></h2>' /*
*/ , '<h3><a href="chf%20MP-cmc-01.htm#P45_2994" target="_top">Disease Prevention and Screening</a></h3>' /*
*/ , '<h3><a href="chf%20MP-cmc-01.htm#P48_5188" target="_top">Diagnosis and Referral </a></h3>' /*
*/ , '<h2><a href="chf%20MP-cmc-02.htm#P76_12051" target="_top">Treatment Guidelines</a></h2>' /*
*/ , '<h2><a href="chf%20MP-cmc-03.htm#P85_16771" target="_top">Major-Market Profiles </a></h2>' /*
*/ , '<h3><a href="chf%20MP-cmc-03.htm#P86_16793" target="_top">United States </a></h3>' /*
*/ , '<h3><a href="chf%20MP-cmc-03.htm#P92_19859" target="_top">France </a></h3>' /*
*/ , '<h3><a href="chf%20MP-cmc-03.htm#P99_24404" target="_top">Germany </a></h3>' /*
*/ , '<h3><a href="chf%20MP-cmc-03.htm#P105_27369" target="_top">Italy </a></h3>' /*
*/ , '<h3><a href="chf%20MP-cmc-03.htm#P112_31655" target="_top">Spain</a></h3>' /*
*/ , '<h3><a href="chf%20MP-cmc-03.htm#P117_34646" target="_top">United Kingdom</a></h3>' /*
*/ , '<h3><a href="chf%20MP-cmc-03.htm#P126_39532" target="_top">Japan</a></h3>' /*
*/ , '<h1><a href="CHF-UN_cmc.htm#P0_0" target="_top">6. Unmet Needs</a></h1>' /*
*/ , '<h2><a href="CHF-UN_cmc.htm#P7_1160" target="_top">Overview</a></h2>' /*
*/ , '<h3><a href="CHF-UN_cmc.htm#P9_1882" target="_top">More-Efficacious Agents for Classes III and IV Patients </a></h3>' /*
*/ , '<h3><a href="CHF-UN_cmc.htm#P12_2963" target="_top">Increased Use of Existing Drugs in Classes I and II </a></h3>' /*
*/ , '<h3><a href="CHF-UN_cmc.htm#P15_4760" target="_top">Improved Diagnosis </a></h3>' /*
*/ , '<h3><a href="CHF-UN_cmc.htm#P18_6145" target="_top">Improved Compliance </a></h3>' /*
*/ , '<h3><a href="CHF-UN_cmc.htm#P21_7756" target="_top">Improved Surgery </a></h3>' /*
*/ , '<h1><a href="chf%20ET-cmc.htm#P0_0" target="_top">7. Emerging Therapies</a></h1>' /*
*/ , '<h2><a href="chf%20ET-cmc.htm#P6_944" target="_top"><img src="Table%20of%20Contents-9t.gif" border="0" width="96" height="63"></a></h2>' /*
*/ , '<h2><a href="chf%20ET-cmc-01.htm#P8_944" target="_top"><img src="Table%20of%20Contents-10t.gif" border="0" width="96" height="54"></a></h2>' /*
*/ , '<h2><a href="chf%20ET-cmc-02.htm#P9_944" target="_top">Emerging Therapies Overview</a></h2>' /*
*/ , '<h2><a href="chf%20ET-cmc-03.htm#P576_7866" target="_top">Angiotensin II Receptor Antagonists </a></h2>' /*
*/ , '<h3><a href="chf%20ET-cmc-03.htm#P577_7902" target="_top">Overview</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-03.htm#P579_9720" target="_top">Mechanism of Action</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-03.htm#P581_10793" target="_top">Telmisartan</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-03.htm#P584_12451" target="_top">Irbesartan</a></h3>' /*
*/ , '<h2><a href="chf%20ET-cmc-04.htm#P587_13672" target="_top">Vasopeptidase Inhibitors </a></h2>' /*
*/ , '<h3><a href="chf%20ET-cmc-04.htm#P588_13697" target="_top">Overview</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-04.htm#P590_14814" target="_top">Mechanism of Action</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-04.htm#P594_16416" target="_top">Omapatrilat </a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-04.htm#P600_20154" target="_top">Gemopatrilat </a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-04.htm#P602_20615" target="_top">MDL-100240 </a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-04.htm#P604_20947" target="_top">AVE-7688</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-04.htm#P606_21803" target="_top">Sampatrilat</a></h3>' /*
*/ , '<h2><a href="chf%20ET-cmc-05.htm#P608_22274" target="_top">Arginine Vasopressin Receptor Antagonists</a></h2>' /*
*/ , '<h3><a href="chf%20ET-cmc-05.htm#P609_22315" target="_top">Overview</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-05.htm#P612_23143" target="_top">Mechanism of Action</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-05.htm#P615_23933" target="_top">Conivaptan</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-05.htm#P621_26470" target="_top">Tolvaptan </a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-05.htm#P627_29295" target="_top">SR-121463 </a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-05.htm#P629_29941" target="_top">OPC-21268</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-05.htm#P631_30354" target="_top">OPC-31260</a></h3>' /*
*/ , '<h2><a href="chf%20ET-cmc-06.htm#P633_30685" target="_top">Endothelin Receptor Antagonists</a></h2>' /*
*/ , '<h3><a href="chf%20ET-cmc-06.htm#P634_30716" target="_top">Overview</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-06.htm#P636_31127" target="_top">Mechanism of Action </a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-06.htm#P639_31967" target="_top">Bosentan </a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-06.htm#P643_32999" target="_top">J-104132 </a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-06.htm#P645_33587" target="_top">Sitaxsentan </a></h3>' /*
*/ , '<h2><a href="chf%20ET-cmc-07.htm#P649_34532" target="_top">Adenosine A1 Receptor Antagonists </a></h2>' /*
*/ , '<h3><a href="chf%20ET-cmc-07.htm#P650_34566" target="_top">Overview</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-07.htm#P652_35297" target="_top">Mechanism of Action</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-07.htm#P655_35936" target="_top">BG9928 (Adentri)</a></h3>' /*
*/ , '<h2><a href="chf%20ET-cmc-08.htm#P659_36810" target="_top">Anti-TNF-α Agents </a></h2>' /*
*/ , '<h3><a href="chf%20ET-cmc-08.htm#P660_36829" target="_top">Overview </a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-08.htm#P662_37217" target="_top">Mechanism of Action</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-08.htm#P664_37671" target="_top">Etanercept </a></h3>' /*
*/ , '<h2><a href="chf%20ET-cmc-09.htm#P667_39057" target="_top">Nonspecific Auto-Antigen Stimulation</a></h2>' /*
*/ , '<h3><a href="chf%20ET-cmc-09.htm#P668_39093" target="_top">Overview</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-09.htm#P670_39465" target="_top">Mechanism of Action</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-09.htm#P672_40350" target="_top">Celacade</a></h3>' /*
*/ , '<h2><a href="chf%20ET-cmc-10.htm#P675_41499" target="_top">Natriuretic Peptides</a></h2>' /*
*/ , '<h3><a href="chf%20ET-cmc-10.htm#P676_41519" target="_top">Overview</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-10.htm#P678_42403" target="_top">Mechanism of Action</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-10.htm#P680_43279" target="_top">Recombinant BNP (Nesiritide) </a></h3>' /*
*/ , '<h2><a href="chf%20ET-cmc-11.htm#P685_44765" target="_top">Inotropic Agents </a></h2>' /*
*/ , '<h3><a href="chf%20ET-cmc-11.htm#P686_44782" target="_top">Overview</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-11.htm#P689_45781" target="_top">Mechanism of Action</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-11.htm#P693_47202" target="_top">Levosimendan</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-11.htm#P701_53254" target="_top">Enoximone </a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-11.htm#P705_55315" target="_top">Oxypurinol</a></h3>' /*
*/ , '<h2><a href="chf%20ET-cmc-12.htm#P712_57690" target="_top">Dual Neutral Endopeptidase/Endothelin-Converting Enzyme Inhibitors</a></h2>' /*
*/ , '<h3><a href="chf%20ET-cmc-12.htm#P713_57756" target="_top">Overview</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-12.htm#P715_57970" target="_top">Mechanism of Action</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-12.htm#P718_58667" target="_top">SLV-306</a></h3>' /*
*/ , '<h2><a href="chf%20ET-cmc-13.htm#P721_59287" target="_top">Dopamine D2 Receptor Agonists</a></h2>' /*
*/ , '<h3><a href="chf%20ET-cmc-13.htm#P722_59316" target="_top">Overview</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-13.htm#P724_60750" target="_top">Mechanism of Action</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-13.htm#P726_61059" target="_top">Nolomirole</a></h3>' /*
*/ , '<h2><a href="chf%20ET-cmc-14.htm#P728_62218" target="_top">Advanced Glycosylation End-Point Breakers</a></h2>' /*
*/ , '<h3><a href="chf%20ET-cmc-14.htm#P729_62259" target="_top">Overview</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-14.htm#P731_62805" target="_top">Mechanism of Action</a></h3>' /*
*/ , '<h3><a href="chf%20ET-cmc-14.htm#P733_63041" target="_top">ALT-711</a></h3>' /*
*/ , '<h1><a href="CHF-MKTcmc.htm#P5_0" target="_top">8. Market Outlook</a></h1>' /*
*/ , '<h2><a href="CHF-MKTcmc.htm#P12_1200" target="_top">Overview</a></h2>' /*
*/ , '<h2><a href="CHF-MKTcmc-01.htm#P27_5555" target="_top">Drug-Class-Specific Trends</a></h2>' /*
*/ , '<h3><a href="CHF-MKTcmc-01.htm#P28_5581" target="_top">Angiotensin-Converting Enzyme Inhibitors</a></h3>' /*
*/ , '<h3><a href="CHF-MKTcmc-01.htm#P32_7215" target="_top">Angiotensin II Receptor Antagonists</a></h3>' /*
*/ , '<h3><a href="CHF-MKTcmc-01.htm#P37_9005" target="_top">Beta Blockers</a></h3>' /*
*/ , '<h3><a href="CHF-MKTcmc-01.htm#P40_10052" target="_top">Diuretics</a></h3>' /*
*/ , '<h3><a href="CHF-MKTcmc-01.htm#P44_10660" target="_top">Aldosterone Antagonists </a></h3>' /*
*/ , '<h3><a href="CHF-MKTcmc-01.htm#P47_11662" target="_top">Inotropic Agents</a></h3>' /*
*/ , '<h3><a href="CHF-MKTcmc-01.htm#P50_12388" target="_top">Vasopeptidase Inhibitors</a></h3>' /*
*/ , '<h3><a href="CHF-MKTcmc-01.htm#P52_12897" target="_top">Arginine Vasopressin Antagonists</a></h3>' /*
*/ , '<h3><a href="CHF-MKTcmc-01.htm#P55_13356" target="_top">Natriuretic Peptides</a></h3>' /*
*/ , '<h2><a href="CHF-MKTcmc-02.htm#P57_13644" target="_top">Region-Specific Trends </a></h2>' /*
*/ , '<h1><a href="Bibiography.htm#P0_0" target="_top">Appendix A. Bibliography—Chronic Heart Failure</a></h1>' /*
*/ , '<h1><a href="Experts%20Interviewed.htm#P0_0" target="_top">Appendix C. Experts Interviewed—Chronic Heart Failure</a></h1>' /*
*/ , '<h1><a href="Market%20Forecast%20Methodology.htm#P0_0" target="_top">Appendix B. Market Forecast Methodology</a></h1>' /*
*/ , '<h2><a href="Market%20Forecast%20Methodology.htm#P1_39" target="_top">General Statement About Patient Population</a></h2>' /*
*/ , '<h2><a href="Market%20Forecast%20Methodology-01.htm#P3_469" target="_top">General Sources of Data </a></h2>' /*
*/ , '<h2><a href="Market%20Forecast%20Methodology-02.htm#P5_1007" target="_top">Definitions of Agents Included in Class Categories </a></h2>' /*
*/ , '<h2><a href="Market%20Forecast%20Methodology-03.htm#P8_1260" target="_top">General Statements About Pricing</a></h2>' /*
*/ , '<h2><a href="Market%20Forecast%20Methodology-04.htm#P31_3491" target="_top">Pricing Assumptions </a></h2>' /*
*/ , '<h3><a href="Market%20Forecast%20Methodology-04.htm#P36_4308" target="_top">Days of Therapy and Compliance</a></h3>' /*
*/ , '<h3><a href="Market%20Forecast%20Methodology-04.htm#P39_5234" target="_top">Emerging Therapy Prices</a></h3>' /*
*/ , '<h2><a href="Market%20Forecast%20Methodology-05.htm#P42_5870" target="_top">Significant Events Impacting the Disease Marketplace</a></h2>' /*
*/ , '<h3><a href="Market%20Forecast%20Methodology-05.htm#P43_5922" target="_top">Percentage Diagnosed</a></h3>' /*
*/ , '<h3><a href="Market%20Forecast%20Methodology-05.htm#P45_6470" target="_top">Percentage Drug-Treated</a></h3>' /*
*/ , '<h3><a href="Market%20Forecast%20Methodology-05.htm#P47_6882" target="_top">Patient Share</a></h3>' /*<!-- TRANSIT - INFOAFTER -->
</body>
</html> */
The tree_nodes.js (final).
var TREE_NODES = [
f(["Executive Summary", "chf-ES.htm", null,
f(["Key Findings", "chf-ES.htm", null]),
f(["What are the key parameters of the CHF market?", "chf-ES-cmc-00.htm", null]),
f(["What are the factors driving the market for CHF therapies?", "chf-ES-01.htm", null]),
f(["What factors are constraining the market for CHF therapies?", "chf-ES-02.htm", null]),
f(["What are the drug development activities of note in CHF?", "chf-ES-03.htm", null]),
f(["What do the experts say?", "chf-ES-04.htm", null]),
f(["What key challenges and opportunities remain?", "chf-ES-05.htm", null])
]),
f(["Introduction", "Pharmacor-Chapter-Head.htm", null,{format:{isFolder:true}}]),
f(["Etiology & Pathophysiology", "CHF-EP-cmc.htm", null,
f(["Key Findings", "CHF-EP-cmc.htm", null]),
f(["Overview", "CHF-EP-cmc-00.htm", null]),
f(["Anatomy", "chf-EP-cmc-01.htm", null]),
f(["Etiology", "CHF-EP-cmc-02.htm", null,
f(["Causes of Chronic Heart Failure", "CHF-EP-cmc-02.htm#P13_3767", null]),
f(["Clinical Characterization of Chronic Heart Failure", "CHF-EP-cmc-02.htm#P18_5924", null])
]),
f(["Pathophysiology", "CHF-EP-cmc-03.htm", null,
f(["Sympathetic Nervous System", "CHF-EP-cmc-03.htm#P25_9608", null]),
f(["Renin-Angiotensin-Aldosterone System", "CHF-EP-cmc-03.htm#P28_10921", null]),
f(["Natriuretic Peptides", "CHF-EP-cmc-03.htm#P34_13615", null]),
f(["Endothelin-1", "CHF-EP-cmc-03.htm#P37_14887", null]),
f([{id:1234}, "Immunomodulator Activity in CHF", "CHF-EP-cmc-03.htm#P39_15408", null])
]) ]),
f(["Epidemiology", "epi-mock-up-cmc.htm", null,
f(["Key Findings", "epi-mock-up-cmc.htm", null]),
f(["Overview", "epi-mock-up-cmc-00.htm", null]),
f(["Disease Definition", "epi-mock-up-cmc-01.htm", null]),
f(["Methodology Overview", "epi-mock-up-cmc-02.htm", null]),
f(["Major-Market Profiles", "epi-mock-up-cmc-03.htm", null,
f(["United States", "epi-mock-up-cmc-03.htm#P62_16890", null]),
f(["France", "epi-mock-up-cmc-03.htm#P65_18532", null]),
f(["Germany", "epi-mock-up-cmc-03.htm#P67_19000", null]),
f(["Italy", "epi-mock-up-cmc-03.htm#P70_20039", null]),
f(["Spain", "epi-mock-up-cmc-03.htm#P72_21293", null]),
f(["United Kingdom", "epi-mock-up-cmc-03.htm#P75_23563", null]),
f(["Japan", "epi-mock-up-cmc-03.htm#P80_26567", null])
]),
f(["Subpopulations","epi-mock-up-cmc-04.htm", null])
]),
f(["Current Therapies", "CHF-CT-cmc.htm", null,
f(["Key Findings", "CHF-CT-cmc.htm", null]),
f(["Overview", "CHF-CT-cmc-00.htm", null]),
f(["Angiotensin-Converting Enzyme Inhibitors", "CHF-CT-cmc-01.htm", null,
f(["Overview", "CHF-CT-cmc-01.htm#P17_3230", null]),
f(["Mechanism of Action", "CHF-CT-cmc-01.htm#P23_6331", null]),
f(["Ramipril", "CHF-CT-cmc-01.htm#P27_9912", null]),
f(["Enalapril", "CHF-CT-cmc-01.htm#P31_11868", null]),
f(["Lisinopril", "CHF-CT-cmc-01.htm#P36_14438", null])
]),
f(["Angiotensin II Receptor Antagonists","CHF-CT-cmc-02.htm", null,
f(["Overview", "CHF-CT-cmc-02.htm#P40_15708", null]),
f(["Mechanism of Action", "CHF-CT-cmc-02.htm#P42_16829", null]),
f(["Valsartan", "CHF-CT-cmc-02.htm#P44_17837", null]),
f(["Candesartan", "CHF-CT-cmc-02.htm#P50_22036", null])
]),
f(["Diuretics","CHF-CT-cmc-03.htm", null,
f(["Overview", "CHF-CT-cmc-03.htm#P57_26296", null]),
f(["Mechanism of Action", "CHF-CT-cmc-03.htm#P61_28399", null]),
f(["Furosemide", "CHF-CT-cmc-03.htm#P63_29545", null]),
f(["Chlorothiazide", "CHF-CT-cmc-03.htm#P65_30276", null])
]),
f(["Aldosterone Antagonists","CHF-CT-cmc-04.htm", null,
f(["Overview", "CHF-CT-cmc-04.htm#P68_30945", null]),
f(["Mechanism of Action", "CHF-CT-cmc-03.htm#P61_28399", null]),
f(["Spironolactone", "CHF-CT-cmc-04.htm#P73_33147", null]),
f(["Eplerenone", "CHF-CT-cmc-04.htm#P77_35246", null])
]),
f(["Beta Blockers ","CHF-CT-cmc-05.htm", null,
f(["Overview", "CHF-CT-cmc-03.htm#P57_26296", null]),
f(["Mechanism of Action", "CHF-CT-cmc-05.htm#P83_38452", null]),
f(["Carvedilol", "CHF-CT-cmc-05.htm#P85_39243", null]),
f(["Metoprolol", "CHF-CT-cmc-05.htm#P89_41813", null]),
f(["Bisoprolol", "CHF-CT-cmc-05.htm#P92_43636", null])
]),
f(["Inotropic Agents","CHF-CT-cmc-06.htm", null,
f(["Overview", "CHF-CT-cmc-06.htm#P96_45127", null]),
f(["Mechanism of Action", "CHF-CT-cmc-06.htm#P98_45758", null]),
f(["Digoxin", "CHF-CT-cmc-06.htm#P100_46806", null])
]),
f(["Nonpharmacological Approaches ","CHF-CT-cmc-07.htm", null])
]),
f(["Medical Practice", "chf-MP-cmc.htm", null,
f(["Key Findings", "chf-MP-cmc.htm", null]),
f(["Overview", "chf-MP-cmc-01.htm", null,
f(["Disease Prevention and Screening", "chf-MP-cmc-01.htm#P45_2994", null]),
f(["Diagnosis and Referral", "chf-MP-cmc-01.htm#P48_5188", null])
]),
f(["Treatment Guidelines","chf-MP-cmc-02.htm", null]),
f(["Major-Market Profiles","chf-MP-cmc-03.htm", null,
f(["United States", "chf-MP-cmc-03.htm#P86_16793", null]),
f(["France", "chf-MP-cmc-03.htm#P92_19859", null]),
f(["Germany", "chf-MP-cmc-03.htm#P99_24404", null]),
f(["Italy", "chf-MP-cmc-03.htm#P105_27369", null]),
f(["Spain", "chf-MP-cmc-03.htm#P112_31655", null]),
f(["United Kingdom", "chf-MP-cmc-03.htm#P117_34646", null]),
f(["Japan", "chf-MP-cmc-03.htm#P126_39532", null])
]) ]),
f(["Unmet Needs", "CHF-UN_cmc.htm", null,
f(["Key Findings", "CHF-UN_cmc.htm", null]),
f(["Overview", "CHF-UN_cmc-00.htm", null,
f(["More-Efficacious Agents for Classes III and IV Patients", "CHF-UN_cmc-00.htm#P9_1882", null]),
f(["Increased Use of Existing Drugs in Classes I and II", "CHF-UN_cmc-00.htm#P12_2963", null]),
f(["Improved Diagnosis", "CHF-UN_cmc-00.htm#P15_4760", null]),
f(["Improved Compliance", "CHF-UN_cmc-00.htm#P18_6145", null]),
f(["Improved Surgery", "CHF-UN_cmc-00.htm#P21_7756", null])
]) ]),
f(["Emerging Therapies", "chf-ET-cmc.htm", null,
f(["Key Findings", "chf-ET-cmc.htm", null]),
f(["Emerging Therapies Overview", "chf-ET-cmc-02.htm", null]),
f(["Angiotensin II Receptor Antagonists", "chf-ET-cmc-03.htm", null,
f(["Overview", "chf-ET-cmc-03.htm#P577_7902", null]),
f(["Mechanism of Action", "chf-ET-cmc-03.htm#P579_9720", null]),
f(["Telmisartan", "chf-ET-cmc-03.htm#P581_10793", null]),
f(["Irbesartan", "chf-ET-cmc-03.htm#P584_12451", null])
]),
f(["Vasopeptidase Inhibitors", "chf-ET-cmc-04.htm", null,
f(["Overview", "chf-ET-cmc-04.htm#P588_13697", null]),
f(["Mechanism of Action", "chf-ET-cmc-04.htm#P590_14814", null]),
f(["Omapatrilat", "chf-ET-cmc-04.htm#P594_16416", null]),
f(["Gemopatrilat", "chf-ET-cmc-04.htm#P600_20154", null]),
f(["MDL-100240", "chf-ET-cmc-04.htm#P602_20615", null]),
f(["AVE-7688", "chf-ET-cmc-04.htm#P604_20947", null]),
f(["Sampatrilat", "chf-ET-cmc-04.htm#P606_21803", null])
]),
f(["Arginine Vasopressin Receptor Antagonists", "chf-ET-cmc-05.htm", null,
f(["Overview", "chf-ET-cmc-05.htm#P609_22315", null]),
f(["Mechanism of Action", "chf-ET-cmc-05.htm#P612_23143", null]),
f(["Conivaptan", "chf-ET-cmc-05.htm#P615_23933", null]),
f(["Tolvaptan", "chf-ET-cmc-05.htm#P621_26470", null]),
f(["SR-121463", "chf-ET-cmc-05.htm#P627_29295", null]),
f(["OPC-21268", "chf-ET-cmc-05.htm#P629_29941", null]),
f(["OPC-31260", "chf-ET-cmc-05.htm#P631_30354", null])
]),
f(["Endothelin Receptor Antagonists", "chf-ET-cmc-06.htm", null,
f(["Overview", "chf-ET-cmc-06.htm#P634_30716", null]),
f(["Mechanism of Action", "chf-ET-cmc-06.htm#P636_31127", null]),
f(["Bosentan", "chf-ET-cmc-06.htm#P639_31967", null]),
f(["J-104132", "chf-ET-cmc-06.htm#P643_32999", null]),
f(["Sitaxsentan", "chf-ET-cmc-06.htm#P645_33587", null])
]),
f(["Adenosine A1 Receptor Antagonists", "chf-ET-cmc-07.htm", null,
f(["Overview", "chf-ET-cmc-07.htm#P650_34566", null]),
f(["Mechanism of Action", "chf-ET-cmc-07.htm#P652_35297", null]),
f(["BG9928 (Adentri)", "chf-ET-cmc-07.htm#P655_35936", null])
]),
f(["Anti-TNF-\u03b1 Agents", "chf-ET-cmc-08.htm", null,
f(["Overview", "chf-ET-cmc-08.htm#P660_36829", null]),
f(["Mechanism of Action", "chf-ET-cmc-08.htm#P662_37217", null]),
f(["Etanercept", "chf-ET-cmc-08.htm#P664_37671", null])
]),
f(["Nonspecific Auto-Antigen Stimulation", "chf-ET-cmc-09.htm", null,
f(["Overview", "chf-ET-cmc-09.htm#P668_39093", null]),
f(["Mechanism of Action", "chf-ET-cmc-09.htm#P670_39465", null]),
f(["Celacade", "chf-ET-cmc-09.htm#P672_40350", null])
]),
f(["Natriuretic Peptides", "chf-ET-cmc-10.htm", null,
f(["Overview", "chf-ET-cmc-10.htm#P676_41519", null]),
f(["Mechanism of Action", "chf-ET-cmc-10.htm#P678_42403", null]),
f(["Recombinant BNP (Nesiritide)", "chf-ET-cmc-10.htm#P680_43279", null])
]),
f(["Inotropic Agents", "chf-ET-cmc-11.htm", null,
f(["Overview", "chf-ET-cmc-11.htm#P686_44782", null]),
f(["Mechanism of Action", "chf-ET-cmc-11.htm#P689_45781", null]),
f(["Levosimendan", "chf-ET-cmc-11.htm#P693_47202", null]),
f(["Enoximone", "chf-ET-cmc-11.htm#P701_53254", null]),
f(["Oxypurinol", "chf-ET-cmc-11.htm#P705_55315", null])
]),
f(["Dual Neutral Endopeptidase/Endothelin-Converting Enzyme Inhibitors", "chf-ET-cmc-12.htm", null,
f(["Overview", "chf-ET-cmc-12.htm#P713_57756", null]),
f(["Mechanism of Action", "chf-ET-cmc-12.htm#P715_57970", null]),
f(["SLV-306", "chf-ET-cmc-12.htm#P718_58667", null])
]),
f(["Dopamine D2 Receptor Agonists", "chf-ET-cmc-13.htm", null,
f(["Overview", "chf-ET-cmc-13.htm#P722_59316", null]),
f(["Mechanism of Action", "chf-ET-cmc-13.htm#P724_60750", null]),
f(["Nolomirole", "chf-ET-cmc-13.htm#P726_61059", null])
]),
f(["Advanced Glycosylation End-Point Breakers", "chf-ET-cmc-14.htm", null,
f(["Overview", "chf-ET-cmc-14.htm#P729_62259", null]),
f(["Mechanism of Action", "chf-ET-cmc-14.htm#P731_62805", null]),
f(["ALT-711", "chf-ET-cmc-14.htm#P733_63041", null])
]) ]),
f(["Market Outlook", "CHF-MKTcmc.htm", null,
f(["Key Findings", "CHF-MKTcmc.htm", null]),
f(["Overview", "CHF-MKTcmc-00.htm", null]),
f(["Drug-Class-Specific Trends", "CHF-MKTcmc-01.htm", null,
f(["Angiotensin-Converting Enzyme Inhibitors", "CHF-MKTcmc-01.htm#P28_5581", null]),
f(["Angiotensin II Receptor Antagonists", "CHF-MKTcmc-01.htm#P32_7215", null]),
f(["Beta Blockers", "CHF-MKTcmc-01.htm#P37_9005", null]),
f(["Diuretics", "CHF-MKTcmc-01.htm#P40_10052", null]),
f(["Aldosterone Antagonists", "CHF-MKTcmc-01.htm#P44_10660", null]),
f(["Inotropic Agents", "CHF-MKTcmc-01.htm#P47_11662", null]),
f(["Vasopeptidase Inhibitors", "CHF-MKTcmc-01.htm#P50_12388", null]),
f(["Arginine Vasopressin Antagonists", "CHF-MKTcmc-01.htm#P52_12897", null]),
f(["Natriuretic Peptides", "CHF-MKTcmc-01.htm#P55_13356", null])
]),
f(["Region-Specific Trends", "CHF-MKTcmc-02.htm", null])
]),
f(["Bibliography", "Bibiography.htm", null,{format:{isFolder:true}}]),
f(["Experts Interviewed", "Experts%20Interviewed.htm", null,{format:{isFolder:true}}]),
f(["Market Forecast Methodology", "Market-Forecast-Methodology.htm", null,
f(["General Statement About Patient Population", "Market-Forecast-Methodology.htm", null]),
f(["General Sources of Data", "Market-Forecast-Methodology-01.htm", null]),
f(["Definitions of Agents Included in Class Categories", "Market-Forecast-Methodology-02.htm", null]),
f(["General Statements About Pricing", "Market-Forecast-Methodology-03.htm", null]),
f(["Pricing Assumptions", "Market-Forecast-Methodology-04.htm", null,
f(["Days of Therapy and Compliance", "Market-Forecast-Methodology-04.htm#P36_4308", null]),
f(["Emerging Therapy Prices", "Market-Forecast-Methodology-04.htm#P39_5234", null]) ]),
f(["Significant Events Impacting the Disease Marketplace", "Market-Forecast-Methodology-05.htm", null,
f(["Percentage Diagnosed", "Market-Forecast-Methodology-05.htm#P43_5922", null]),
f(["Percentage Drug-Treated", "Market-Forecast-Methodology-05.htm#P45_6470", null]),
f(["Patient Share", "Market-Forecast-Methodology-05.htm#P47_6882", null])
]),
f(["Market Assumptions","Market%20Assumptions.htm",null])
])
];
Thanks